In particular, we have shown that KCa3.1-blockade via oral Senicapoc administration was able to significantly reduce acute allergen-dependent bronchoconstriction, the allergen-dependent increase in lung resistance, and airway hyperresponsiveness (AHR) to carbachol. The gene discussed is KCNN4; the disease is airway hyperresponsiveness.